Analysts Set Expectations for ANRO Q1 Earnings

Alto Neuroscience, Inc. (NYSE:ANRO) – Stock analysts at William Blair issued their Q1 2026 EPS estimates for shares of Alto Neuroscience in a report issued on Friday, March 21st. William Blair analyst M. Minter forecasts that the company will earn ($0.53) per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Alto Neuroscience’s current full-year earnings is ($2.54) per share. William Blair also issued estimates for Alto Neuroscience’s Q2 2026 earnings at ($0.53) EPS, Q3 2026 earnings at ($0.43) EPS and Q4 2026 earnings at ($0.43) EPS.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Thursday, March 20th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.09.

Alto Neuroscience Price Performance

Shares of ANRO opened at $2.65 on Monday. The business’s 50-day moving average is $3.60 and its 200-day moving average is $5.98. The company has a debt-to-equity ratio of 0.05, a current ratio of 13.10 and a quick ratio of 13.09. The company has a market capitalization of $71.34 million and a price-to-earnings ratio of -1.04. Alto Neuroscience has a fifty-two week low of $2.58 and a fifty-two week high of $18.35.

Institutional Investors Weigh In On Alto Neuroscience

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN raised its holdings in shares of Alto Neuroscience by 40.0% during the fourth quarter. Wells Fargo & Company MN now owns 10,989 shares of the company’s stock worth $46,000 after acquiring an additional 3,139 shares in the last quarter. Deutsche Bank AG grew its stake in Alto Neuroscience by 31.3% in the 4th quarter. Deutsche Bank AG now owns 15,210 shares of the company’s stock valued at $64,000 after buying an additional 3,629 shares during the last quarter. BNP Paribas Financial Markets grew its position in shares of Alto Neuroscience by 619.2% in the third quarter. BNP Paribas Financial Markets now owns 4,315 shares of the company’s stock valued at $49,000 after purchasing an additional 3,715 shares during the last quarter. Rhumbline Advisers grew its holdings in Alto Neuroscience by 24.4% in the 4th quarter. Rhumbline Advisers now owns 25,556 shares of the company’s stock valued at $108,000 after buying an additional 5,008 shares during the last quarter. Finally, Philadelphia Financial Management of San Francisco LLC raised its stake in Alto Neuroscience by 1.5% during the 3rd quarter. Philadelphia Financial Management of San Francisco LLC now owns 449,952 shares of the company’s stock valued at $5,147,000 after purchasing an additional 6,663 shares during the last quarter.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.